Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data.
Maria GontikaCharalampos SkarlisNikolaos MarkoglouMaria-Eleftheria EvangelopoulosGeorge VelonakisGeorge P ChrousosMarinos DalakasLeonidas StefanisMaria C AnagnostouliPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021)
Our preliminary results support that response of POMS patients to fingolimod may be partially dependent on age and previous DMT, with younger and treatment-naïve patients presenting worse outcomes. The role of immunogenetics and immunophenotyping in personalized treatment warrants investigation in larger and more diverse populations.
Keyphrases
- multiple sclerosis
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- young adults
- type diabetes
- mental health
- machine learning
- metabolic syndrome
- big data
- patient reported outcomes
- artificial intelligence
- deep learning
- glycemic control
- middle aged
- white matter
- smoking cessation